buprenorphine + methadone

Buprenorphine + methadone refers to the concurrent use of two opioid medications, each with distinct pharmacological profiles, primarily in the context of opioid use disorder (OUD) treatment. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor, exhibiting a ceiling effect that limits its maximal efficacy and risk for respiratory depression. Methadone is a full agonist at the mu-opioid receptor, providing more potent opioid effects without a ceiling effect. Both drugs are used as medication-assisted treatment (MAT) for OUD to reduce withdrawal symptoms and cravings[4][5][6]. Combining these agents is generally not recommended due to potential pharmacodynamic interactions: buprenorphine can displace methadone from receptors, potentially precipitating withdrawal or reducing analgesic efficacy; both drugs also carry risks of additive sedation and rare but serious cardiac arrhythmias such as QT prolongation[1][2][3][4]. The combination does not represent an approved fixed-dose product but may occur in clinical practice during transitions between therapies or inadvertently.